223 related articles for article (PubMed ID: 34648119)
1. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
Schoenbeck KL; Flynn KE
Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
[TBL] [Abstract][Full Text] [Related]
2. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia.
Efficace F; Iurlo A; Patriarca A; Stagno F; Bee PC; Ector G; Capodanno I; Elena C; Bonifacio M; Blijlevens NMA; Caocci G; Wan C; Abruzzese E; Breccia M; Cottone F; Okumura I; Oerlemans S; Cascavilla N; Albano F; Kota V; Sztankay M; Miggiano MC; Saussele S; Di Renzo N; Sorà F; Castagnetti F; Baccarani M; Vignetti M; Rosti G
Leuk Lymphoma; 2021 Mar; 62(3):669-678. PubMed ID: 33153355
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
Efficace F; Stagno F; Iurlo A; Breccia M; Cottone F; Bonifacio M; Abruzzese E; Castagnetti F; Caocci G; Crugnola M; Capodanno I; Martino B; Tiribelli M; Patriarca A; Gozzini A; Pregno P; Saussele S; Cascavilla N; Fozza C; Bergamaschi M; Binotto G; Vignetti M; Rosti G
Leukemia; 2020 Feb; 34(2):488-498. PubMed ID: 31477798
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
5. Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Efficace F; Vignetti M; Sparano F; Scalzulli E; Breccia M
Expert Rev Hematol; 2021 Mar; 14(3):293-302. PubMed ID: 33554672
[No Abstract] [Full Text] [Related]
6. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
7. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
Yu L; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
[No Abstract] [Full Text] [Related]
8. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
[TBL] [Abstract][Full Text] [Related]
9. Low-dose tyrosine kinase inhibitors before treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study.
Cayssials E; Torregrosa-Diaz J; Gallego-Hernanz P; Tartarin F; Systchenko T; Maillard N; Desmier D; Machet A; Fleck E; Corby A; Motard C; Denis G; Herbelin A; Gombert JM; Roy L; Ragot S; Leleu X; Guilhot F; Chomel JC
Cancer; 2020 Aug; 126(15):3438-3447. PubMed ID: 32459375
[TBL] [Abstract][Full Text] [Related]
10. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
Efficace F; Baccarani M; Breccia M; Saussele S; Abel G; Caocci G; Guilhot F; Cocks K; Naeem A; Sprangers M; Oerlemans S; Chie W; Castagnetti F; Bombaci F; Sharf G; Cardoni A; Noens L; Pallua S; Salvucci M; Nicolatou-Galitis O; Rosti G; Mandelli F
Qual Life Res; 2014 Apr; 23(3):825-36. PubMed ID: 24026634
[TBL] [Abstract][Full Text] [Related]
11. Chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Zhang Q; Li Z; Hou Y; Dang H; Chen J; Liang L; Wang Q; Cao C; Zhao H; Gui R; Zu Y; Zhou J; Yu F; Wang J; Song Y; Zhang Y
Ann Palliat Med; 2022 Apr; 11(4):1336-1350. PubMed ID: 35523742
[TBL] [Abstract][Full Text] [Related]
12. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Flynn KE; Myers JM; D'Souza A; Schiffer CA; Thompson JE; Atallah E
Oncologist; 2019 Sep; 24(9):1253-1258. PubMed ID: 30944185
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.
Bostan H; Toptas T; Tanrikulu FP; Kut K; Arikan F; Yilmaz F; Atagunduz I; Firatli-Tuglular T
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):836-842. PubMed ID: 32958432
[TBL] [Abstract][Full Text] [Related]
14. How could patient reported outcomes improve patient management in chronic myeloid leukemia?
De Marchi F; Medeot M; Fanin R; Tiribelli M
Expert Rev Hematol; 2017 Jan; 10(1):9-14. PubMed ID: 27858461
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
16. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Réa D; Boquimpani C; Mauro MJ; Minami Y; Allepuz A; Maheshwari VK; D'Alessio D; Wu Y; Lawrance R; Narbutas S; Sharf G; Hochhaus A
Leukemia; 2023 May; 37(5):1060-1067. PubMed ID: 37069326
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a medication management service in improving adherence to tyrosine kinase inhibitors and clinical outcomes of patients with chronic myeloid leukaemia: a randomised controlled trial.
Tan BK; Chua SS; Chen LC; Chang KM; Balashanker S; Bee PC
Support Care Cancer; 2020 Jul; 28(7):3237-3247. PubMed ID: 31734798
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.
Efficace F; Cardoni A; Cottone F; Vignetti M; Mandelli F
Leuk Res; 2013 Feb; 37(2):206-13. PubMed ID: 23177797
[TBL] [Abstract][Full Text] [Related]
20. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.
Malagola M; Iurlo A; Bucelli C; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; De Gobbi M; Romano A; Tiribelli M; Russo Rossi A; Russo S; Defina M; Farina M; Bernardi S; Butturini G; Pellizzeri S; Roccaro AM; Russo D
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):323-331. PubMed ID: 38369436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
